You are here

Structural & Congenital Heart Disease


Patients who received a mechanical prosthesis for surgical replacement of aortic or mitral valves derived a significant long-term survival benefit versus those who received a biologic prosthesis, according to a study in the New England Journal of Medicine.

Nearly half of all valve hospitals in the U.S. are misclassified as either low- or high-performing, according to research published in JAMA Cardiology—but that problem might have a simple fix.

DENVER — Transcatheter aortic valve replacement (TAVR) is an “economically dominant” strategy compared to surgical aortic valve replacement (SAVR) for patients with aortic stenosis at intermediate surgical risk, according to data presented by David J. Cohen, MD, MSc, Oct. 31 at the Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium.

Research examining 278 patients with in-stent restenosis (ISR) found that drug-eluting balloon (DEB) was non-inferior in comparison with drug-eluting stent (DES) in terms of six-month minimal lumen diameter (MLD).

DENVER — Measuring frailty could lead to more accurate predictions of outcomes following transcatheter aortic valve replacement (TAVR) than a validated risk algorithm, according to research presented Oct. 30 at the annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium.


Recent Headlines

TCT: Abbot CMO Simonton touts DES results, talks valve replacement The long-awaited SPRIT IV one-year results, presented at the recent Transcatheter Cardiovascular Therapeutics (TCT) conference in San Francicso, for Abbotts Xience V drug-eluting stent (DES) over Boston Scientifics Taxus DES found a stent thrombosis rate of 0.29 percent, which surprised even Chuck Simonton, Abbotts chief medical officer.
TCT: Aortic valve implants have very low complication rates up to one year SAN FRANCISCOMid-term valve-related complications are exceptionally low, and the gradient release after transcatheter aortic valve prosthesis implantation is stable up to one year of follow up, according to a study presented this week at the 2009 Transcatheter Cardiovascular Therapeutics meeting.
TCT: Transcatheter valve therapy explodes, standardization sought SAN FRANSISCOAn estimated 10,000 transcatheter heart valves have been implanted in patients with critical valvular aortic stenosis, and the researchers, who have their eyes on U.S. approval, are now seeking to standardize the techniques and trial expectations, according to a presentation by Martin B. Leon, MD, at the 21st annual Transcatheter Cardiovascular Therapeutics (TCT) symposium.